Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”) the Agile
Clinical Trial Operating System™, today reported its financial
results for the quarter ended June 30, 2022.
"We made meaningful strides across our strategic
priorities in the second quarter and our pathway to profitability.
We believe this commitment has materialized into strong revenue
growth, sales pipeline expansion, and notably, margin improvement
and sustainable cash burn,” said David Coman, Chief Executive
Officer of Science 37. “We remain focused on leading the way as a
pioneer in agile clinical trials with an eye on our objective of
long-term profitability, and we are confident that Science 37 is
well-positioned to deliver durable value for our shareholders.”
Quarterly Financial Highlights
- Revenue was $19.3 million for the quarter ended June 30,
2022, a 54% increase compared to the same period in 2021.
- Net bookings were $25.4 million for the quarter ended
June 30, 2022, compared to $44.1 million for the same period
in 2021.
- Adjusted gross profit(1) was $5.9 million for the quarter ended
June 30, 2022, compared to $5.4 million for the same period in
2021. Adjusted gross margin(1) was 30.6% for the quarter ended
June 30, 2022, compared to 43.2% percent for the same period
in the prior year, and up from 17.2% for the first quarter of
2022.
- Net loss was $5.8 million for the quarter ended June 30,
2022, resulting in loss per share of $0.05, compared to a net loss
of $7.7 million in the same period in 2021, or loss per share of
$1.07. Net loss for the quarter ended June 30, 2022 included a
non-cash gain of $20.9 million resulting from revaluation of the
earn-out liability.
- Adjusted net loss(1) was $20.9 million for the quarter ended
June 30, 2022, compared to an adjusted net loss of $7.2
million in the same period in 2021.
- Adjusted EBITDA(1) was $(16.5) million for the quarter ended
June 30, 2022, compared to $(5.4) million in the same period
in 2021. Adjusted EBITDA for the quarter ended June 30, 2022
showed a 17% improvement from the first quarter of 2022 that had an
Adjusted EBITDA of $(19.8) million.
- Cash and Cash Equivalents as of June 30, 2022 were $148.3
million.
Net bookings for the quarter ended June 30, 2022
were impacted by a strategic shift in sales strategy to focus on
larger studies, which generally have a longer bookings conversion
timeline.
The decreases in adjusted gross margin, adjusted
EBITDA and adjusted net loss for the quarter ended June 30,
2022 as compared to the quarter ended June 30, 2021 were
primarily due to the planned ongoing investments in our operating
system and commercialization of the products to support expansion
of existing and new commercial opportunities, investment in patient
recruitment capabilities, as well as the additional cost burden as
a result of becoming a publicly traded company in the fourth
quarter of 2021.
(1) Adjusted gross profit, adjusted gross margin,
adjusted net loss and adjusted EBITDA are non-GAAP financial
measures. For a reconciliation to the most directly comparable GAAP
measure, please refer to "Reconciliation of GAAP to non-GAAP
measures" section included in this press release.
Full Year 2022 Financial
Outlook
Science 37 is providing revenue guidance of $76
million to $86 million and adjusted EBITDA guidance of $(65)
million to $(69) million for the fiscal year ending
December 31, 2022.
The foregoing 2022 Financial Outlook statement
represents management's current estimate as of the date of this
release. Actual results may differ materially depending on a number
of factors. Investors are urged to read the Cautionary Note
Regarding Forward-Looking Statements included in this release.
Management does not assume any obligation to update these
estimates.
Science 37 has not provided a quantitative
reconciliation of adjusted EBITDA guidance to net (income) loss on
a forward-looking basis within this press release because the
Company is unable, without unreasonable efforts, to provide
reconciling information with respect to interest income,
depreciation, amortization, stock-based compensation, restructuring
costs and change in fair value of the Earn-Out liability, all of
which are adjustments to adjusted EBITDA. These items, which could
materially affect the computation of forward-looking GAAP net
income (loss), are inherently uncertain and depend on various
factors, some of which are outside of the Science 37’s control.
Webcast and Conference Call
Details
Science 37 will host a conference call today,
August 11, 2022, at 8:30 a.m. ET to discuss its second quarter 2022
financial results. The conference call can be accessed by
registering online for dial-in information or via live audio
webcast at:
https://investors.science37.com/news-events/events-presentations.
Participants interested in dialing in to the conference call are
requested to register at a minimum 15 minutes before the start of
the call to obtain a unique pin for the call.
A replay of the call will be available via webcast
for on-demand listening shortly after the completion of the call,
at the same web link, and will remain available for approximately
90 days.
About Science 37
Science 37’s mission is to enable universal access
to clinical research—making it easier for patients and providers to
participate from anywhere and helping to accelerate the development
of treatments that impact patient lives. As a pioneer of
decentralized clinical trials, the Science 37 Agile Clinical Trial
Operating System (OS) supports today’s more agile clinical research
designs with its full stack, end-to-end technology platform and
specialized networks of patient communities, telemedicine
investigators, mobile nursing, remote coordinators, community
providers, and data and devices. Configurable to enable almost any
study type, the Science 37 OS enables up to 15x faster enrollment,
28% better retention and 3x more diverse patient population, as
compared to the traditional site-centric clinical trial model, with
industry-leading workflow orchestration, evidence generation and
data harmonization. For more information, visit
https://www.science37.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains certain forward-looking
statements within the meaning of the federal securities laws,
including statements regarding the products offered by Science 37,
its sales pipeline expansion and the markets in which it operates
and expects to enter, and Science 37’s anticipated growth and
profitability, cash burn rate, projected future results, and
revenue and adjusted EBITDA guidance for fiscal year 2022. These
forward-looking statements generally are identified by the words
“believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result”
and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) the ability to maintain the listing of Science 37’s
securities on Nasdaq, (ii) volatility in the price of Science 37’s
securities due to a variety of factors, including changes in the
competitive and highly regulated industries in which Science 37
operates, variations in performance across competitors, changes in
laws and regulations affecting Science 37’s business and changes in
its capital structure, and general economic and financial market
conditions, including fluctuations in currency exchange rates,
economic instability, and inflationary conditions, (iii) the
ability to implement business plans, forecasts, and other
expectations, and to identify and realize additional opportunities,
(iv) the risk that Science 37 may never achieve or sustain
profitability, (v) the risk that Science 37 will need to raise
additional capital to execute its business plan, which may not be
available on acceptable terms or at all, and (vi) the potential
adverse effects of the ongoing global COVID-19 pandemic. The
foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of our Annual
Report on Form 10-K for the fiscal year ended December 31,
2021 filed with the U.S. Securities and Exchange Commission (the
“SEC”) on March 22, 2022 and in our other documents filed by
Science 37 from time to time with the SEC. These filings identify
and address other important risks and uncertainties that could
cause actual events and results to differ materially from those
contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Science 37 assumes no obligation and does not intend to update
or revise these forward-looking statements, whether as a result of
new information, future events, or otherwise, except as required by
law. Science 37 does not give any assurance that Science 37 will
achieve its expectations.
Use of Non-GAAP Financial Measures and Key
Performance Measures
In addition to the financial measures prepared in
accordance with U.S. Generally Accepted Accounting Principles
("GAAP"), this press release contains certain non-GAAP financial
measures, including adjusted gross profit, adjusted gross margin,
adjusted EBITDA and adjusted net income (loss). A “non-GAAP
financial measure” is generally defined as a numerical measure of a
company’s financial performance that excludes or includes amounts
from the most directly comparable measure calculated and presented
in accordance with GAAP in the statements of operations, balance
sheets, or statements of cash flows of the Company. Please refer to
the reconciliations of the non-GAAP financial measures to their
most directly comparable GAAP measures included in this press
release and the accompanying tables contained at the end of this
release.
The Company defines adjusted gross profit as gross
profit excluding stock-based compensation expense. The Company
defines adjusted gross margin as gross margin excluding stock-based
compensation expense.
The Company defines adjusted net income (loss)
(including adjusted diluted earnings per share) as net income
(loss) (including diluted earnings per share) excluding
transactions that the Company believes are not representative of
its core operations, namely: restructuring and other costs;
transaction and integration-related expenses; stock-based
compensation expense; other income (expense), net; and gain or loss
on extinguishment of debt.
EBITDA represents earnings before interest, taxes,
depreciation, and amortization. The Company defines adjusted EBITDA
as EBITDA, further adjusted to exclude expenses and transactions
that the Company believes are not representative of its core
operations, namely: restructuring and other costs; transaction and
integration-related expenses; stock-based compensation expense;
other income (expense), net; and gain or loss on extinguishment of
debt.
Each of the non-GAAP measures noted above are used
by management and the Board to evaluate the Company's core
operating results because they exclude certain items whose
fluctuations from period-to-period do not necessarily correspond to
changes in the core operations of the business.
Management believes that adjusted gross profit,
adjusted gross margin, adjusted EBITDA and adjusted net income
(loss) are helpful to investors, analysts, and other interested
parties because they can assist in providing a more consistent and
comparable overview of our operations across our historical
periods. In addition, these measures are frequently used by
analysts, investors, and other interested parties to evaluate and
assess performance.
Non-GAAP measures have limitations in that they do
not reflect all of the amounts associated with the Company's
results of operations as determined in accordance with GAAP. Also,
other companies might calculate these measures differently.
This press release also contains certain key
performance measures which we use to evaluate our business and
results, measure performance, identify trends, formulate plans and
make strategic decisions. We believe that the presentation of such
metrics is useful to the Company’s investors because they are used
to measure and model the performance of companies such as ours. Net
bookings represent new business awards, net of contract
modifications, contract cancellations, and other adjustments. Net
bookings represent the minimum contractual value for the initial
planned duration of a contract as of the contract execution date.
The minimum fixed fees, upfront implementation fees and technology
and support fees are included in net bookings. Estimates of
variable revenue for utilization in excess of the contracted
amounts is not included in the value of net bookings. Net bookings
vary from period to period depending on numerous factors, including
customer authorization volume, sales performance and the overall
health of the life sciences industry, among others.
Contacts:
INVESTOR RELATIONS:Caroline
PaulGilmartin Groupinvestors@science37.com
MEDIA INQUIRIES:Drew BustosScience
37Phone: (610) 417-6953Email: pr@science37.com
SCIENCE 37 HOLDINGS, INC. and
SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS(unaudited)
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
(In thousands, except per share data) |
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
Revenue |
$ |
19,275 |
|
|
$ |
12,547 |
|
|
$ |
37,961 |
|
|
$ |
24,986 |
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
Cost of revenue |
|
13,842 |
|
|
|
7,289 |
|
|
|
29,828 |
|
|
|
15,928 |
|
Selling, general and administrative |
|
28,183 |
|
|
|
11,382 |
|
|
|
58,337 |
|
|
|
20,545 |
|
Depreciation and amortization |
|
4,230 |
|
|
|
1,776 |
|
|
|
7,699 |
|
|
|
3,273 |
|
Total operating expenses |
|
46,255 |
|
|
|
20,447 |
|
|
|
95,864 |
|
|
|
39,746 |
|
|
|
|
|
|
|
|
|
Loss from operations |
|
(26,980 |
) |
|
|
(7,900 |
) |
|
|
(57,903 |
) |
|
|
(14,760 |
) |
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
Interest income |
|
95 |
|
|
|
1 |
|
|
|
189 |
|
|
|
1 |
|
Sublease income |
|
240 |
|
|
|
181 |
|
|
|
479 |
|
|
|
214 |
|
Change in fair value of earn-out liability |
|
20,900 |
|
|
|
— |
|
|
|
96,400 |
|
|
|
— |
|
Other income (expense), net |
|
(88 |
) |
|
|
3 |
|
|
|
(105 |
) |
|
|
4 |
|
Total other income (expense), net |
|
21,147 |
|
|
|
185 |
|
|
|
96,963 |
|
|
|
219 |
|
Income (loss) before income
taxes |
|
(5,833 |
) |
|
|
(7,715 |
) |
|
|
39,060 |
|
|
|
(14,541 |
) |
Income tax expense
(benefit) |
|
— |
|
|
|
— |
|
|
|
(1 |
) |
|
|
— |
|
Net income (loss) |
$ |
(5,833 |
) |
|
$ |
(7,715 |
) |
|
$ |
39,061 |
|
|
$ |
(14,541 |
) |
|
|
|
|
|
|
|
|
Earnings (loss) per
share: |
|
|
|
|
|
|
|
Basic |
$ |
(0.05 |
) |
|
$ |
(1.07 |
) |
|
$ |
0.34 |
|
|
$ |
(2.32 |
) |
Diluted |
$ |
(0.05 |
) |
|
$ |
(1.07 |
) |
|
$ |
0.31 |
|
|
$ |
(2.32 |
) |
|
|
|
|
|
|
|
|
Weighted average common shares
outstanding: |
|
|
|
|
|
|
|
Basic |
|
115,995 |
|
|
|
7,187 |
|
|
|
115,693 |
|
|
|
6,258 |
|
Diluted |
|
115,995 |
|
|
|
7,187 |
|
|
|
126,185 |
|
|
|
6,258 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SCIENCE 37 HOLDINGS, INC. and
SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE
SHEETS
|
(unaudited) |
|
|
(In thousands, except share
data) |
June 30,2022 |
|
December 31,2021 |
Assets |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
148,329 |
|
|
$ |
214,601 |
|
Accounts receivable and unbilled services, net |
|
13,173 |
|
|
|
10,699 |
|
Prepaid expenses and other current assets |
|
7,810 |
|
|
|
7,403 |
|
Total current assets |
|
169,312 |
|
|
|
232,703 |
|
Property and equipment,
net |
|
1,225 |
|
|
|
1,393 |
|
Operating lease right-of-use
assets |
|
1,519 |
|
|
|
2,086 |
|
Capitalized software, net |
|
37,298 |
|
|
|
24,290 |
|
Other assets |
|
152 |
|
|
|
326 |
|
Total assets |
$ |
209,506 |
|
|
$ |
260,798 |
|
Liabilities,
redeemable convertible preferred stock and stockholders’
equity |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ |
9,238 |
|
|
$ |
12,819 |
|
Accrued expenses and other liabilities |
|
11,698 |
|
|
|
17,073 |
|
Deferred revenue |
|
5,213 |
|
|
|
5,130 |
|
Total current liabilities |
|
26,149 |
|
|
|
35,022 |
|
Non-current liabilities: |
|
|
|
Deferred revenue |
|
2,390 |
|
|
|
2,478 |
|
Operating lease liabilities |
|
1,028 |
|
|
|
1,322 |
|
Other long-term liabilities |
|
1,592 |
|
|
|
1,477 |
|
Long-term earn-out liability |
|
2,500 |
|
|
|
98,900 |
|
Total liabilities |
|
33,659 |
|
|
|
139,199 |
|
|
|
|
|
Redeemable convertible
preferred stock: |
|
|
|
Redeemable convertible preferred stock, $0.0001 par value;
100,000,000 shares authorized, 0 issued and outstanding at
June 30, 2022 and December 31, 2021, respectively |
|
— |
|
|
|
— |
|
Stockholders’
equity: |
|
|
|
Common stock, $0.0001 par value; 400,000,000 shares authorized,
116,252,431 and 114,991,026 issued and outstanding at June 30,
2022 and December 31, 2021, respectively |
|
12 |
|
|
|
11 |
|
Additional paid-in capital |
|
338,825 |
|
|
|
323,666 |
|
Accumulated other comprehensive income |
|
27 |
|
|
|
— |
|
Accumulated deficit |
|
(163,017 |
) |
|
|
(202,078 |
) |
Total stockholders’
equity |
|
175,847 |
|
|
|
121,599 |
|
Total liabilities, redeemable
convertible preferred stock and stockholders’ equity |
$ |
209,506 |
|
|
$ |
260,798 |
|
|
|
|
|
|
|
|
|
SCIENCE 37 HOLDINGS, INC. and
SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS(unaudited)
|
Six Months Ended June 30, |
(In thousands) |
|
2022 |
|
|
|
2021 |
|
Cash flows from
operating activities: |
|
|
|
Net income (loss) |
$ |
39,061 |
|
|
$ |
(14,541 |
) |
Adjustments to reconcile net
income (loss) to net cash used in operating activities: |
|
|
|
Depreciation and amortization |
|
7,699 |
|
|
|
3,273 |
|
Non-cash lease expense related to operating lease right-of-use
assets |
|
567 |
|
|
|
878 |
|
Stock-based compensation |
|
13,687 |
|
|
|
915 |
|
Gain on change in fair value of earn-out liability |
|
(96,400 |
) |
|
|
— |
|
Gain on foreign currency exchange rates |
|
104 |
|
|
|
— |
|
Provision for doubtful accounts |
|
32 |
|
|
|
125 |
|
Changes in operating assets
and liabilities: |
|
|
|
Accounts receivable and unbilled services |
|
(2,507 |
) |
|
|
4,937 |
|
Prepaid expenses and other current assets |
|
(378 |
) |
|
|
(1,719 |
) |
Other assets |
|
94 |
|
|
|
(142 |
) |
Accounts payable |
|
(6,250 |
) |
|
|
(1,162 |
) |
Accrued expenses and other current liabilities |
|
(5,879 |
) |
|
|
(2,814 |
) |
Deferred revenue |
|
(5 |
) |
|
|
907 |
|
Operating lease liabilities |
|
(294 |
) |
|
|
(605 |
) |
Other, net |
|
115 |
|
|
|
945 |
|
Net cash used in operating activities |
|
(50,354 |
) |
|
|
(9,003 |
) |
Cash flows from
investing activities: |
|
|
|
Payments related to
capitalized software development costs |
|
(16,228 |
) |
|
|
(6,117 |
) |
Purchases of property and
equipment |
|
(159 |
) |
|
|
(385 |
) |
Net cash used in investing activities |
|
(16,387 |
) |
|
|
(6,502 |
) |
Cash flows from
financing activities: |
|
|
|
Proceeds from stock option
exercises |
|
472 |
|
|
|
1,133 |
|
Net cash provided by financing activities |
|
472 |
|
|
|
1,133 |
|
Net decrease in cash and cash
equivalents |
|
(66,269 |
) |
|
|
(14,372 |
) |
Effect of foreign currency
exchange rate changes on cash |
|
(3 |
) |
|
|
— |
|
Cash and cash equivalents,
beginning of period |
|
214,601 |
|
|
|
33,483 |
|
Cash and cash equivalents, end
of period |
$ |
148,329 |
|
|
$ |
19,111 |
|
Supplemental
disclosures of non-cash activities |
|
|
|
Balance in accounts payable,
accrued expenses and other current liabilities, and capitalized
stock-based compensation related to capitalized software and fixed
asset additions |
$ |
(4,152 |
) |
|
$ |
(948 |
) |
Right-of-use asset obtained in
exchange for operating lease liabilities |
$ |
— |
|
|
$ |
(1,305 |
) |
Balance in prepaid expenses
and other current assets related to stock option exercises |
$ |
28 |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
SCIENCE 37 HOLDINGS, INC. and
SUBSIDIARIESReconciliation of GAAP to Non-GAAP
Measures(Unaudited)
The following table provides reconciliation of
adjusted gross profit and adjusted gross margin to gross profit and
gross margin, the most directly comparable GAAP measures,
respectively:
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
(In thousands) |
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
Revenue |
$ |
19,275 |
|
|
$ |
12,547 |
|
|
$ |
37,961 |
|
|
$ |
24,986 |
|
|
|
|
|
|
|
|
|
Gross
profit |
$ |
5,433 |
|
|
$ |
5,258 |
|
|
$ |
8,133 |
|
|
$ |
9,058 |
|
Stock-based compensation
(2) |
$ |
462 |
|
|
$ |
162 |
|
|
$ |
976 |
|
|
$ |
217 |
|
Adjusted gross
profit |
$ |
5,895 |
|
|
$ |
5,420 |
|
|
$ |
9,109 |
|
|
$ |
9,275 |
|
|
|
|
|
|
|
|
|
Gross
margin |
|
28.2 |
% |
|
|
41.9 |
% |
|
|
21.4 |
% |
|
|
36.3 |
% |
Adjusted gross
margin |
|
30.6 |
% |
|
|
43.2 |
% |
|
|
24.0 |
% |
|
|
37.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following table provides reconciliation of
adjusted EBITDA to net income (loss), the most directly comparable
GAAP measure:
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
(In thousands) |
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
Net income (loss) |
$ |
(5,833 |
) |
|
$ |
(7,715 |
) |
|
$ |
39,061 |
|
|
$ |
(14,541 |
) |
Interest income |
|
(95 |
) |
|
|
(1 |
) |
|
|
(189 |
) |
|
|
(1 |
) |
Depreciation and
amortization |
|
4,230 |
|
|
|
1,776 |
|
|
|
7,699 |
|
|
|
3,273 |
|
Other income (1) |
|
(21,052 |
) |
|
|
(184 |
) |
|
|
(96,774 |
) |
|
|
(218 |
) |
Stock-based compensation |
|
6,130 |
|
|
|
690 |
|
|
|
13,687 |
|
|
|
915 |
|
Franchise taxes |
|
127 |
|
|
|
— |
|
|
|
179 |
|
|
|
— |
|
Provision for income
taxes |
|
— |
|
|
|
— |
|
|
|
(1 |
) |
|
|
— |
|
Adjusted
EBITDA |
$ |
(16,493 |
) |
|
$ |
(5,434 |
) |
|
$ |
(36,338 |
) |
|
$ |
(10,572 |
) |
The following table provides reconciliation of
adjusted net loss to net income (loss), the most directly
comparable GAAP measure:
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
(In thousands) |
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
Net income (loss) |
$ |
(5,833 |
) |
|
$ |
(7,715 |
) |
|
$ |
39,061 |
|
|
$ |
(14,541 |
) |
Interest income |
|
(95 |
) |
|
|
(1 |
) |
|
|
(189 |
) |
|
|
(1 |
) |
Other income (1) |
|
(21,052 |
) |
|
|
(184 |
) |
|
|
(96,774 |
) |
|
|
(218 |
) |
Stock-based compensation
expense |
|
6,130 |
|
|
|
690 |
|
|
|
13,687 |
|
|
|
915 |
|
Adjusted net
loss |
$ |
(20,850 |
) |
|
$ |
(7,210 |
) |
|
$ |
(44,215 |
) |
|
$ |
(13,845 |
) |
_____________________________________(1) Includes
a gain of $20.9 million and $96.4 million recorded for the three
and six months ended June 30, 2022 associated with the change
in the fair value of the earn-out liability.
(2) Represents the portion of total stock-based
compensation recorded within cost of revenues.
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Sep 2023 to Sep 2024